Prevenar 20 20 mg Suspension for injection.
PDF Leaflet Revision Date: 22 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Active immunisation against pneumococcal disease in individuals from 6 weeks of age.
Dosage (summary)
0.5 mL for adults and children; specific schedules for infants and children under 5 years.
Special Populations
- Immunocompromised
- Preterm infants
Pregnancy & Breastfeeding
Use in pregnancy only if benefits outweigh risks; unknown if excreted in breast milk.
Key Drug Interactions
- Influenza vaccine
- COVID-19 mRNA vaccine
Contraindications
- Hypersensitivity to components
Common side effects
- Irritability
- Drowsiness
- Pain at injection site
- Decreased appetite
- Fever
Counselling Points
- Monitor for allergic reactions post-vaccination
- Complete vaccination series as recommended
Serious warnings
- Risk of anaphylaxis
- Postpone vaccination during acute severe febrile illness
Important Disclaimer
The Prevenar 20 20 mg Suspension for injection. professional information leaflet below is the property of Pfizer Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
